Table 1 Patient Demographics (n = 160 CP-CML).

From: Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients

Age

Median (Range) : 36 years (18–65)

Sex

Males: 108; Females: 52

Sokal Score

Low (< 0.8) N = 49

Intermediate (0.8–1.2) N = 61

High (> 1.2) N = 50

Median follow-up (range)

83 (12–120 months)

Karyotype at diagnosis

Only 9;22 n = 128

t(9;22)with additional chromosome abnormalities n = 18

Not available N = 14

BCR-ABL1 Fusion transcript

e13a2 type

51

e14a2 type

109

Drug

Glivec

140

Veenat

20

Back to article page